Neoadjuvant, spare-adjuvant (NASA) in stage IIIB-IV (M1a) melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with melanoma (a type of skin cancer) that has spread to lymph nodes or nearby areas but can be completely removed with surgery.
- You have not had prior treatment with certain immunotherapies (PD-1 or CTLA-4 inhibitors).
- You do not have an active autoimmune disease that requires immunosuppressive treatment, though you may take up to 10 mg of prednisone daily.
- You are generally well enough to undergo treatment, with a performance status of 0-2 (able to care for yourself and perform daily activities).
- Your organ function (blood counts, kidney, liver, heart) is adequate as determined by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can help people with high-risk melanoma. It is for patients whose melanoma has not spread and who have not had prior treatment for melanoma.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.